Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study
| Autor: | Florian Buggle, Christoph Lichy, Andreas Ruf, Sven Reiners, Armin J. Grau |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Blood Platelets
Male medicine.medical_specialty Lacunar stroke Ticlopidine Platelet Membrane Glycoproteins Brain Ischemia Antigens CD Internal medicine medicine Secondary Prevention Humans Platelet cardiovascular diseases Platelet activation Stroke Advanced and Specialized Nursing Aspirin Cross-Over Studies business.industry Tetraspanin 30 Middle Aged medicine.disease Clopidogrel Flow Cytometry Platelet Activation Crossover study P-Selectin Anesthesia Case-Control Studies Cardiology Platelet aggregation inhibitor Drug Therapy Combination Female Neurology (clinical) Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Stroke. 34(4) |
| ISSN: | 1524-4628 |
| Popis: | Background and Purpose— Combined antiplatelet agents may offer additive protection over single drugs after stroke. We investigated whether platelet activation is reduced under combined aspirin and clopidogrel compared with each drug alone. Methods— In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks. Platelet function in whole blood was studied after each treatment period and in healthy control subjects to assess activation-dependent antigens CD62p and CD63 by flow cytometry and collagen/epinephrine (CEPI-CT) and collagen/ADP (CADP-CT) closure times with the platelet function analyzer PFA-100, which investigates platelet-related function under shear stress. Results— CD62p expression and CD63 expression were not different under the 3 treatment regimens. CD63 but not CD62p expression was lower in control subjects than in stroke patients regardless of the antiplatelet treatment ( P P P =0.0009) or clopidogrel ( P =0.0074) or in control subjects ( P =0.0010), mainly because of strong prolongation in a patient subgroup (28%). Conclusions— CD63 expression reflecting the release of platelet lysosomes is consistently increased after stroke and incompletely suppressed by treatment with aspirin, clopidogrel, or both. The strong prolongation of CADP-CT under combined aspirin and clopidogrel in a patient subgroup may indicate a lower risk of thrombosis but also a higher risk of hemorrhage. The predictive value of platelet activation parameters requires investigation in prospective studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|